Skip to main content
SpringerLink
Log in

Current Therapies for Osteoporosis

  • Chapter
Clinical Trials in Osteoporosis

Part of the book series: Clinical Trials ((CLINICAL))

Abstract

This chapter concentrates on contemporary evidence for the effectiveness of pharmacological interventions to reduce fracture risk in subjects with osteoporosis. The management of such subjects is placed in the context of the pressures to contain the cost of healthcare while managing the personal and health economic consequences to subjects and society. It is argued that the financial consequences are underestimated in our current health economic models. Osteoporosis is a relatively new clinical area that is perhaps best viewed as a preventable and treatable risk factor for fragility fracture. Treatments with robust evidence from randomized, controlled trials (RCTs) have only become available in the last 20 years, and the most widely prescribed legacy treatment, in the form of hormone-replacement therapy (HRT), is rarely used nowadays. This chapter does not dwell on the public health issues associated with the prevention of osteoporosis and the attainment and maintenance of optimum bone health through exercise, diet, and avoidance of smoking and excess alcohol. These are important issues, but they are beyond the scope of this pharmacological view. The interaction between osteoporosis and falls is, however, briefly considered because both are risk factors for fracture.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Burge, R.T., Worley, D., Johansen, A. et al. (2001). The cost of osteoporotic fractures in the UK: projections for 2000–2020. J Drug Assessment 4:71–160.

    Google Scholar 

  2. Kanis, J., Brazier, J., Stevenson, M. et al. (2002). Treatment of established osteoporosis: a systematic review and cost-utility analysis. http://www.ncchta.org/execsumm/summ629.htm (accessed 4 May 2006). Health Tech Assessment 6(29).

    Google Scholar 

  3. Lawrence, T.M., White, C.T., Wenn, R. et al. (2005). The current hospital costs of treating hip fractures. Injury 36:88–91.

    Article  PubMed  Google Scholar 

  4. Department of Health (2005). Hospital Episode Statistics (England). http://www.hesonline.nhs.uk/Ease/servlet/DynamicPageBuild?siteID=1802&categoryID=192&catN ame=Free%20data (accessed 27 March 2006).

    Google Scholar 

  5. Elliot-Gibson, V., Bogoch, E.R., Jamal, S.A. et al. (2004). Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int 15:767–78.

    Article  PubMed  CAS  Google Scholar 

  6. Brankin, E., Caroline, M. and Munro R (2005). Closing the osteoporosis management gap in primary care: a secondary prevention of fracture programme Curr Med Res Opin 21:425–82.

    Article  Google Scholar 

  7. No authors listed (1993). Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94:646–50.

    Google Scholar 

  8. Faulkner, K.G. (2005). The tale of the T-score: review and perspective. Osteoporos Int 16:347–52.

    Article  PubMed  Google Scholar 

  9. Masud, T. and Francis, R.M. (2000). The increasing use of peripheral bone densitometry. BMJ 321:396–8.

    Article  PubMed  CAS  Google Scholar 

  10. Stone, K., Seeley, D., Lui, L. et al. (2003). BMD at multiple sites and risk of fracture of multiple types: long-term results from the study of osteoporotic fractures. J Bone Miner Res 18:1947–54.

    Article  PubMed  Google Scholar 

  11. Schuit, S.C.E., van der Klift, M., Weel, A.E.A.M. et al. (2004). Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 34:195–202.

    Article  PubMed  CAS  Google Scholar 

  12. Heaney, R.P. (2003). Is the paradigm shifting? Bone 33:457–65.

    Article  PubMed  Google Scholar 

  13. Cauley, J.A., Seeley, D.G., Ensrud, K. et al. (1995). Estrogen replacement therapy and fractures in older women. Ann Intern Med 122:9–16.

    PubMed  CAS  Google Scholar 

  14. Gallagher, J.C., Rapuri, P.B., Haynatzki, G. et al. (2002). Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. J Clin Endocrinol Metab 87:4914–23.

    Article  PubMed  CAS  Google Scholar 

  15. Writing Group for the Women’s Health Initiative (2002). I. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–33.

    Article  Google Scholar 

  16. Anderson, G.L., Limacher, M., Assaf, A.R. et al. (2004). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291:1701–12.

    Article  PubMed  CAS  Google Scholar 

  17. Stefanick, M.L., Anderson, G.L., Margolis, K.L. et al. (2006). Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295:1647–57.

    Article  PubMed  CAS  Google Scholar 

  18. Ettinger, B., Black, D.M., Mitlak, B.H. et al. (1999). Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282:637–45.

    Article  PubMed  CAS  Google Scholar 

  19. Cummings, S.R., Eckert, S., Krueger, K.A. et al. (1999). The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 281:2189–97.

    Article  PubMed  CAS  Google Scholar 

  20. Riggs, B.L. and Hartmann, L.C. (2003). Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med 348:618–29.

    Article  PubMed  CAS  Google Scholar 

  21. Cauley, J.A., Norton, L., Lippman, M.E. et al. (2001). Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat 65:125–34.

    Article  PubMed  CAS  Google Scholar 

  22. Barrett-Connor, E., Grady, D., Sashegyi, A. et al. (2002). Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 287:847–57.

    Article  PubMed  CAS  Google Scholar 

  23. van Staa, T.P., Abenhaim, L. and Cooper, C. (1998). Use of cyclical etidronate and prevention of non-vertebral fractures. Rheumatology 37:87–94.

    Article  Google Scholar 

  24. Department of Health (2005). Prescription Cost Analysis. http://www.ic.nhs.uk/pubs/prescostanalysis2005 [accessed 20 April 2006].

    Google Scholar 

  25. Black, D.M., Cummings, S.R., Karpf, D.B. et al. (1996). Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535–41.

    Article  PubMed  CAS  Google Scholar 

  26. Cummings, S.R., Black, D.M., Thompson, D.E. et al. (1998). Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077–82.

    Article  PubMed  CAS  Google Scholar 

  27. Orwoll, E., Ettinger, M., Weiss, S. et al. (2000). Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604–10.

    Article  PubMed  CAS  Google Scholar 

  28. Saag, K.G., Emkey, R., Schnitzer, T.J. et al. (1998). Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339:292–9.

    Article  PubMed  CAS  Google Scholar 

  29. Rizzoli, R., Greenspan, S.L., Bone, G., 3rd et al.; The Alendronate Once Weekly Study Group (2002). Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 17:1988–96.

    Article  PubMed  CAS  Google Scholar 

  30. Cranney, A., Wells, G., Willan, A. et al. (2002). II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 23:508–16.

    Article  PubMed  CAS  Google Scholar 

  31. Bone, H.G., Hosking, D., Devogelaer, J.-P. et al. (2004). Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189–99.

    Article  PubMed  CAS  Google Scholar 

  32. Harris, S.T., Watts, N.B., Genant, H.K. et al. (1999). Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 282:1344–52.

    Article  PubMed  CAS  Google Scholar 

  33. Reginster, J.Y., Minne, H.W., Sorensen, O.H. et al. (2000). Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83–91.

    Article  PubMed  CAS  Google Scholar 

  34. Sorensen, O.H., Crawford, G.M., Mulder, H. et al. (2003). Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 32:120–6.

    Article  PubMed  CAS  Google Scholar 

  35. Ste-Marie, L.G., Sod, E., Johnson, T. et al. (2004). Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis. Calcif Tiss Int 75(6):469–76.

    Article  CAS  Google Scholar 

  36. Mellstrom, D.D., Sorensen, O.H., Goemaere, S. et al. (2004). Seven years of treatment with risedronate in women with postmenopausal osteoporosis. CalcifTiss Int 75(6):462–8.

    Article  CAS  Google Scholar 

  37. Cranney, A., Tugwell, P., Adachi, J. et al. (2002). III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 23:517–23.

    Article  PubMed  CAS  Google Scholar 

  38. Boonen, S., McClung, M.R., Eastell, R. et al. (2004). Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. JAm Geriatr Soc 52:1832–9.

    Article  Google Scholar 

  39. Cohen, S., Levy, R.M., Keller, M. et al. (1999). Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42:2309–18.

    Article  PubMed  CAS  Google Scholar 

  40. Reid, D.M., Hughes, R.A., Laan, R.F.J.M. et al. (2000). Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res 15:1006–13.

    Article  PubMed  CAS  Google Scholar 

  41. Wallach, S., Cohen, S., Reid, D.M. et al. (2000). Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tiss Int 67:277–85.

    Article  CAS  Google Scholar 

  42. Harris, S.T., Watts, N.B., Li, Z. et al. (2004). Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr Med Res Opin 20:757–64.

    Article  PubMed  CAS  Google Scholar 

  43. Reid, D.M., Hosking, D., Kendler, D. et al. (2006). Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis: results of FACTS1-International. Clin Drug Invest 26:63–74.

    Article  CAS  Google Scholar 

  44. Taggart, H., Bolognese, M.A., Lindsay, R.L. et al. (2002). Upper gastrointestinal safety of risedronate: a pooled analysis. Mayo Clinic Proc 77:262–70.

    CAS  Google Scholar 

  45. Chesnut, C., 3rd, Skag, A., Christiansen, C. et al. (2004). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241–9.

    Article  CAS  Google Scholar 

  46. Adami, S., Felsenberg, D., Christiansen, C. et al. (2004). Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone 34:881–9.

    Article  PubMed  CAS  Google Scholar 

  47. Epstein, S., Delmas, P.D., Emkey, R. et al. (2006). Oral ibandronate in the management of postmenopausal osteoporosis: Reviewof upper gastrointestinal safety. Maturitas 54:1–10.

    Article  PubMed  CAS  Google Scholar 

  48. Neer, R.M., Arnaud, C.D., Zanchetta, J.R. et al. (2001). Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–41.

    Article  PubMed  CAS  Google Scholar 

  49. Rubin, M.R., Cosman, F., Cosman, F. et al. (2002). The anabolic effects of parathyroid hormone. Osteoporos Int 13:267–77.

    Article  PubMed  CAS  Google Scholar 

  50. Jiang, Y., Zhao, J.J., Mitlak, B.H. et al. (2003). Recombinant human parathyroid hormone (1–34) [Teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18:1932–41.

    Article  PubMed  CAS  Google Scholar 

  51. Ettinger, B., San Martin, J., Crans, G. et al. (2004). Differential effects of Teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745–51.

    Article  PubMed  CAS  Google Scholar 

  52. Lane, N.E., Sanchez, S., Modin, G.W. et al. (1998). Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 102:1627–33.

    PubMed  CAS  Google Scholar 

  53. Orwoll, E.S., Scheele, W.H., Paul, S. et al. (2003). The effect of teriparatide [Human Parathyroid Hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9–17.

    Article  PubMed  CAS  Google Scholar 

  54. Marie, P.J., Ammann, P., Boivin, G. et al. (2001). Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tiss Int 69:121–9.

    Article  CAS  Google Scholar 

  55. Marie, P.J. (2005). Strontium ranelate: a novel mode of action optimizing bone formation and resorption. Osteoporos Int 16:S7–S10.

    Article  PubMed  CAS  Google Scholar 

  56. Nielsen, S.P., Slosman, D., Sorensen, O.H. et al. (1999). Influence of strontium on bone mineral density and bone mineral content measurements by dual X-ray absorptiometry. J Clin Densitom 2:371–9.

    Article  PubMed  CAS  Google Scholar 

  57. Meunier, P.J., Roux, C., Seeman, E. et al. (2004). The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459–68.

    Article  PubMed  CAS  Google Scholar 

  58. Reginster, J.Y., Seeman, E., De Vernejoul, M.C. et al. (2005). Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:2816–22.

    Article  PubMed  CAS  Google Scholar 

  59. Roux, C., Reginster, J.-Y., Fechtenbaum, J. et al. (2006). Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res 21:536–42.

    Article  PubMed  CAS  Google Scholar 

  60. Committee for Proprietary Medicinal Products (CPMAP). European Public Assessment Report. Protelos: scientific discussion [online] http://www.emea.eu.int/ humandocs/PDFs/EPAR/protelos/121604en6.pdf (accessed 18 April 2006).

    Google Scholar 

  61. Heaney, R.P. (2000). Calcium, dairy products and osteoporosis. J Am Coll Nutr 19:83S–99.

    PubMed  CAS  Google Scholar 

  62. Dawson-Hughes, B., Harris, S.S., Krall, E.A. et al. (1997). Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 337:670–6.

    Article  PubMed  CAS  Google Scholar 

  63. Cumming, R.G. and Nevitt, M.C. (1997). Calcium for prevention of osteoporotic fractures in postmenopausal women. J Bone Miner Res 12:1321–9.

    Article  PubMed  CAS  Google Scholar 

  64. Department of Health (1998). Nutrition and bone health: with particular reference to calcium and vitamin D. Report on Health and Social Subjects, 49. London: Department of Health.

    Google Scholar 

  65. Porthouse, J., Cockayne, S., King, C. et al. (2005). Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ 330:1003–6.

    Article  PubMed  CAS  Google Scholar 

  66. The Record Trial Group (2005). Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 365:1621–8.

    Article  CAS  Google Scholar 

  67. Jackson, R.D., LaCroix, A.Z., Gass, M. et al. (2006). Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354:669–83.

    Article  PubMed  CAS  Google Scholar 

  68. Michaelsson, K., Melhus, H., Bellocco, R. et al. (2003). Dietary calcium and vitamin D intake in relation to osteoporotic fracture risk. Bone 32:694–703.

    Article  PubMed  CAS  Google Scholar 

  69. Avenell, A., Gillespie, W., Gillespie, L. et al. (2005). Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. The Cochrane Database of Systematic Reviews Issue 3. CD000227.

    Google Scholar 

  70. Prince, R.L., Devine, A., Dhaliwal, S.S. et al. (2006). Effects of calcium supplementation on clinical fracture and bone structure: results of a 5-year, double-blind, placebocontrolled trial in elderly women. Arch Intern Med 166:869–75.

    Article  PubMed  CAS  Google Scholar 

  71. Brennan, J., Johansen, A., Butler, J. et al. (2003). Place of residence and risk of fracture in older people: a population-based study of over 65-year-olds in Cardiff. Osteoporos Int 14:515–19.

    Article  Google Scholar 

  72. Cali, C.M. and Kiel, D.P. (1995). An epidemiologic study of fall-related fractures among institutionalized older people. J Am Geriatr Soc 43:1336–40.

    PubMed  CAS  Google Scholar 

  73. Chapuy, M.C., Arlot, M.E., Duboeuf, F. et al. (1992). Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 372:1637–42.

    Google Scholar 

  74. Chapuy, M.C., Arlot, M.E., Delmans, P.D. et al. (1994). Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 308:1081–2.

    PubMed  CAS  Google Scholar 

  75. Lilliu, H., Pamphile, R., Chapuy, M.-C. et al. (2003). Calcium-vitamin D3 supplementation is cost-effective in hip fractures prevention. Maturitas 44:299–305.

    Article  PubMed  CAS  Google Scholar 

  76. Lips, P., Graafmans, W.C., Ooms, M.E. et al. (1996). Vitamin D supplementation and fracture incidence in elderly persons: a randomized, placebo-controlled clinical trial. Ann Intern Med 124:400–6.

    PubMed  CAS  Google Scholar 

  77. Flicker, L., MacInnis, R.J., Stein, M.S. et al. (2005). Should older people in residential care receive vitamin D to prevent falls? Results of a randomized trial. J Am Geriatr Soc 53:1881–8.

    Article  PubMed  Google Scholar 

  78. Bischoff-Ferrari, H.A., Willett, W.C., Wong, J.B. et al. (2005). Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 293:2257–64.

    Article  PubMed  CAS  Google Scholar 

  79. Dawson-Hughes, B., Heaney, R.P., Holick, M.F. et al. (2005). Estimates of optimal vitamin D status. Osteoporos Int 16:713–16.

    Article  PubMed  CAS  Google Scholar 

  80. MacLaughlin, J. and Holick, M.F. (1985). Aging decreases the capacity of human skin to produce vitamin D3. J Clin Invest 76:1536–8.

    Article  PubMed  CAS  Google Scholar 

  81. Holick, M.F., Siris, E.S., Binkley, N. et al. (2005). Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 90:3215–24.

    Article  PubMed  CAS  Google Scholar 

  82. Simonelli, C., Weiss, T.W., Morancey, J. et al. (2005). Prevalence of vitamin D inadequacy in a minimal trauma fracture population. Curr Med Res Opin 21:1069–74.

    Article  PubMed  CAS  Google Scholar 

  83. Seton, M., Jackson, V., Lasser, K.E. et al. (2005). Low 25-hydroxyvitamin D and osteopenia are prevalent in persons ≥ 55 yr with fracture at any site: a prospective, observational study of persons fracturing in the community. J Clin Densitom 8:454–60.

    Article  PubMed  Google Scholar 

  84. Dixon, T., Mitchell, P., Beringer, T. et al. (2006). An overview of the prevalence of 25-hydroxy-vitamin D inadequacy amongst elderly patients with or without fragility fracture in the United Kingdom. Curr Med Res Opin 22:405–15.

    Article  PubMed  CAS  Google Scholar 

  85. Bischoff-Ferrari, H.A., Orav, E.J. and Dawson-Hughes, B. (2006). Effect of cholecalciferol plus calcium on falling in ambulatory older men and women: a 3-year randomized controlled trial. Arch Intern Med 166:424–30.

    Article  PubMed  CAS  Google Scholar 

  86. Youm, T., Koval, K.J. and Kummer, F.J., Zuckerman, J.D. (1999). Do all hip fractures result from a fall? Am J Orthop 28:190–4.

    PubMed  CAS  Google Scholar 

  87. Royal College of Physicians and the Bone and Tooth Society of Great Britain (2000). Osteoporosis. Clinical guidelines for prevention and treatment. Update on pharmacological interventions and an algorithm for management. London: Royal College of Physicians.

    Google Scholar 

  88. Scottish Intercollegiate Guidelines Network (2003). Management of osteoporosis: National clinical guideline 71. http://www.sign.ac.uk/guidelines/fulltext/71/index.html (accessed 7 April 2006).

    Google Scholar 

  89. Department of Health (2001). National Service Framework for Older People. London: Department of Health.

    Google Scholar 

  90. Tilyard, M.W., Spears, G.F., Thomson, J. et al. (1992). Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 326:357–62.

    PubMed  CAS  Google Scholar 

  91. National Institute for Health and Clinical Excellence (2005). Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. Technology appraisal guidance 87. London: NICE. Available at http://www.nice.org.uk/page=aspx?o=TA087guidance accessed 23/11/06

    Google Scholar 

  92. Tinetti, M.E., Speechley, M. and Ginter, S.F. (1988). Risk factors for falls among elderly persons living in the community. N Engl J Med 319:1701–7.

    PubMed  CAS  Google Scholar 

  93. Pluijm, S., Smit, J., Tromp, E. et al. (2006). A risk profile for identifying community-dwelling elderly with a high risk of recurrent falling: results of a 3-year prospective study. Osteoporos Int 17:417–25.

    Article  PubMed  CAS  Google Scholar 

  94. Geusens, P., Autier, P., Boonen, S. et al. (2002). The relationship among history of falls, osteoporosis, and fractures in postmenopausal women. Arch Phys Med Rehabil 83:903–6.

    Article  PubMed  Google Scholar 

  95. Chang, J.T., Morton, S.C., Rubenstein, L.Z. et al. (2004). Interventions for the prevention of falls in older adults: systematic review and meta-analysis of randomised clinical trials. BMJ 328:680.

    Article  PubMed  Google Scholar 

  96. Gillespie, L.D., Gillespie, W.J., Robertson, M.C. et al. (2003). Interventions for preventing falls in elderly people. The Cochrane Database of Systematic Reviews Issue 4. CD000340.

    Google Scholar 

  97. Feldstein, A., Elmer, P., Nichols, G. et al. (2005). Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporos Int 16:2168–74.

    Article  PubMed  CAS  Google Scholar 

  98. Aspray, T.J., Stevenson, P., Abdy, S.E. et al. (2006). Low bone mineral density measurements in care home residents—a treatable cause of fractures. Age Ageing 35:37–41.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Education, Health and Sciences, University of Derby, Derby, UK

    Dr Jonathan R. Bayly

Authors
  1. Dr Jonathan R. Bayly
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medical Physics & Clinical Engineering Department, Nottingham University Hospitals NHS Trust, Nottingham, UK

    Derek Pearson BSc, PhD (Joint Service Manager) (Joint Service Manager)

  2. Medical Affairs, Bio-Imaging Technologies Inc., Newtown, PA, USA

    Colin G. Miller PhD, FICR (Sr. Vice President) (Sr. Vice President)

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag London Limited

About this chapter

Cite this chapter

Bayly, J.R. (2007). Current Therapies for Osteoporosis. In: Pearson, D., Miller, C.G. (eds) Clinical Trials in Osteoporosis. Clinical Trials. Springer, London. https://doi.org/10.1007/978-1-84628-587-5_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-84628-587-5_10

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84628-389-5

  • Online ISBN: 978-1-84628-587-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation